Status:
RECRUITING
Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)
Lead Sponsor:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborating Sponsors:
Germans Trias i Pujol Hospital
Conditions:
Fatty Liver
Obesity
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
The objective of this clinical trial, a pilot study, is to assess the impact of nicotinamide (NAM) on individuals with hepatic fibrosis. The main question it aims to answer is: \- To determine if th...
Detailed Description
Patients with a Fibroscan \> 8 kPa will be offered to participate in this study. Participants will receive either placebo or a NAM dose adjusted to body weight. The duration of the treatment is 12 mon...
Eligibility Criteria
Inclusion
- Patients aged between 18 and 85 years.
- Diagnosis of non-alcoholic fatty liver disease (NAFLD) by their referring physicians (NAFLD defined as the presence of hepatic steatosis and in the absence of significant alcohol consumption, having excluded other liver diseases).
- BMI between 27-40 kg/m2.
- Fibroscan® value greater than 9.2 kPa, obtained within the last 6 months prior to the start of the study.
Exclusion
- Patients with any medical condition or illness that, in the opinion of the investigator, could interfere with the study results and/or affect the patients' ability to participate or complete the study.
- History of clinically significant heart disease (ejection fraction \<40% \[normal range 50-70%\], heart failure defined as New York Heart Association \[NYHA\] Class \> 2; clinically significant congenital or acquired valvular disease; symptomatic coronary artery disease such as myocardial infarction or angina, history of unstable arrhythmias, history of atrial fibrillation).
- Decreased renal function (estimated glomerular filtration rate \<45 mL/min/1.73 m2, calculated using the CKD-EPI formula) at screening.
- Alcohol consumption exceeding 30 g/day in men or 20 g/day in women.
- Patients with significant impairment of liver function in the selection analysis defined as repeated values of AST, ALT, and bilirubin \> 3 times the upper limit of normal.
- Positive for hepatitis B surface antigen or hepatitis C antibodies.
- Patients with hepatocellular carcinoma.
- Patients with liver cirrhosis (Fibroscan® \> 18, compatible biopsy, or those who have experienced decompensations of cirrhosis).
- Patients diagnosed with human immunodeficiency virus (HIV).
- Patients with hypersensitivity or a history of severe allergies to NAM or excipients used in the preparation of capsules (NAM and placebo).
- Patients with iodinated contrast allergy.
- History or evidence of an autoimmune disorder considered clinically significant by the investigator or requiring systemic, chronic use of systemic corticosteroids or other immunosuppressants.
- Patients on treatment with hepatotoxic drugs (amiodarone, immunosuppressants, ART, antituberculosis drugs, corticosteroids, etc.).
- Patients consuming narcotic and psychotropic substances with hepatotoxic effects.
- Individuals with incapacitating diseases or cognitive impairment.
- Institutionalized patients or those without a fixed address.
- Principal investigator's discretion in case of indications of low adherence to the trial or follow-up visits.
- Individuals with a life expectancy of less than 12 months.
- Patients participating in another interventional clinical trial, excluding observational/natural history studies, at the start of the study or within the last 30 days before the start of the study.
- Previous use of vitamin B3 (NAM), with abstinence required for at least 3 months before screening.
- Pregnant women as determined by a positive high-sensitivity serum or urine pregnancy test (minimum sensitivity of 25 IU/L or equivalent units of hCG) within 24 hours prior to screening, dosing, or completion of the study. Women of childbearing potential (WOCBP) will undergo a pregnancy test (serum or urine) 24 hours prior to screening, dosing, or completion of the study. Such participants must use a highly effective contraceptive method, such as combined hormonal contraceptives or intrauterine device (IUD), in accordance with the Clinical Trial Facilitation Group, throughout the entire study.
- Breastfeeding women.
- Patients undergoing treatment/supplementation with vitamin E.
- Patients receiving probiotics.
- Patients on the waiting list for bariatric surgery in the next 12 months.
- Patients undergoing treatment with drugs that may have an effect on the progression of liver disease.
- Drugs for the treatment of T2DM with effects on NAFLD (GLP-1 analogs, thiazolidinediones such as pioglitazone) initiated within 6 months before the study start.
- Drugs for the treatment of T2DM with effects on intestinal microbiota (metformin, α-GI inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors) initiated within 6 months before the study start.
- Patients who do not sign the informed consent.
- Patients with contraindications to the contrast agent to be used in imaging tests.
Key Trial Info
Start Date :
April 23 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06599918
Start Date
April 23 2024
End Date
December 1 2028
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain, 08025